These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38378610)

  • 1. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining prevalence and correlates of smoking opioids in British Columbia: opioids are more often smoked than injected.
    Parent S; Papamihali K; Graham B; Buxton JA
    Subst Abuse Treat Prev Policy; 2021 Oct; 16(1):79. PubMed ID: 34663374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study.
    Corser J; Palis H; Fleury M; Lamb J; Lock K; McDougall J; Mehta A; Newman C; Spence H; Buxton JA
    Harm Reduct J; 2022 May; 19(1):46. PubMed ID: 35590375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada.
    Papamihali K; Yoon M; Graham B; Karamouzian M; Slaunwhite AK; Tsang V; Young S; Buxton JA
    Harm Reduct J; 2020 Nov; 17(1):90. PubMed ID: 33228676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
    Kamal A; Ferguson M; Xavier JC; Liu L; Graham B; Lock K; Buxton JA
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):27. PubMed ID: 37194018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario.
    Foreman-Mackey A; Bayoumi AM; Miskovic M; Kolla G; Strike C
    Int J Drug Policy; 2019 Nov; 73():135-140. PubMed ID: 31654936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada.
    Boyd J; Collins AB; Mayer S; Maher L; Kerr T; McNeil R
    Addiction; 2018 Dec; 113(12):2261-2270. PubMed ID: 30211453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overdose Prevention and Housing: a Qualitative Study Examining Drug Use, Overdose Risk, and Access to Safer Supply in Permanent Supportive Housing in Vancouver, Canada.
    Ivsins A; MacKinnon L; Bowles JM; Slaunwhite A; Bardwell G
    J Urban Health; 2022 Oct; 99(5):855-864. PubMed ID: 36044156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social network support and harm reduction activities in a peer researcher-led pilot study, British Columbia, Canada.
    Elkhalifa S; Jozaghi E; Marsh S; Thomson E; Gregg D; Buxton J; Jolly A
    Harm Reduct J; 2020 Aug; 17(1):57. PubMed ID: 32825836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (Re)situating expertise in community-based overdose response: Insights from an ethnographic study of overdose prevention sites (OPS) in Vancouver, Canada.
    Olding M; Boyd J; Kerr T; Fowler A; McNeil R
    Int J Drug Policy; 2023 Jan; 111():103929. PubMed ID: 36529032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating opioid preference to inform safe supply services: A cross sectional study.
    Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia.
    Mema SC; Sage C; Popoff S; Bridgeman J; Taylor D; Corneil T
    Harm Reduct J; 2018 Apr; 15(1):19. PubMed ID: 29625621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating oxygen monitoring and administration during overdose responses at a sanctioned overdose prevention site in San Francisco, California: A mixed-methods study.
    Suen LW; Wenger LD; Morris T; Majano V; Davidson PJ; Browne EN; Ray B; Megerian CE; Lambdin BH; Kral AH
    Int J Drug Policy; 2023 Nov; 121():104165. PubMed ID: 37652815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study.
    Ferguson M; Choisil P; Lamb J; Burmeister C; Newman C; Lock K; Tobias S; Liu L; Buxton JA
    Harm Reduct J; 2023 Dec; 20(1):178. PubMed ID: 38093272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
    Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
    Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing fentanyl-related overdoses and implications for overdose response: Findings from a rapid ethnographic study in Vancouver, Canada.
    Mayer S; Boyd J; Collins A; Kennedy MC; Fairbairn N; McNeil R
    Drug Alcohol Depend; 2018 Dec; 193():69-74. PubMed ID: 30343236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative assessment of tablet injectable opioid agonist therapy (TiOAT) in rural and smaller urban British Columbia, Canada: Motivations and initial impacts.
    Bowles J; Mansoor M; Werb D; Kerr T; Bardwell G
    J Subst Use Addict Treat; 2024 Feb; 157():209185. PubMed ID: 37865289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.